GlassScriptPhysician profile
John D Midgett
NPI 1619149473
$7,163.11
in general payments reported to CMS, 2019-2025
51 companies · $23.43 in 2025
The $23.43 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,345 · 2022: $1,948 · 2023: $1,707 · 2024: $1,140 · 2025: $23.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.40 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $956.39 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $752.79 | 2021-2024 | |
| Lilly USA, LLC | $546.75 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $427.34 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $316.90 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $296.67 | 2021-2023 | |
| Glaxosmithkline, LLC. | $294.64 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $280.00 | 2021-2024 | Trintellix |
| Eisai INC. | $240.97 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.40 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $203.14 | 2022 | |
| Amarin Pharma, INC. | $183.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.87 | 2021-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $150.64 | 2021-2023 | Veozah |
| Bausch Health US, LLC | $140.64 | 2021-2024 | Aplenzin, Wellbutrin |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $137.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $132.31 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $109.76 | 2021 | |
| Merck Sharp & Dohme LLC | $109.04 | 2021-2023 | Belsomra |
| Abbott Laboratories | $107.56 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $104.64 | 2022-2024 | |
| Hikma Pharmaceuticals USA | $83.77 | 2021-2023 | Ryaltris, Mitigare, Kloxxado |
| Adlon Therapeutics L.P. | $82.22 | 2021 | |
| Neos Therapeutics, LP | $81.12 | 2021-2022 | |
| Boston Scientific Corporation | $80.57 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Mylan Specialty L.P. | $71.79 | 2021-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $67.65 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $66.87 | 2024 | Spravato |
| Esperion Therapeutics, INC. | $65.73 | 2021 | |
| Amgen INC. | $62.94 | 2023-2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $58.54 | 2023-2024 | Auvelity |
| Exact Sciences Corporation | $55.85 | 2023-2024 | Cologuard Collection Kit |
| Vbi Vaccine (Delaware) INC. | $50.04 | 2022 | |
| Insulet Corporation | $46.48 | 2023-2024 | Omnipod |
| Sumitomo Pharma America, INC. | $46.12 | 2023-2024 | Gemtesa |
| Alkermes, INC. | $43.54 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $40.74 | 2023-2024 | Edarbyclor, Horizant |
| Teva Pharmaceuticals USA, INC. | $38.21 | 2021-2022 | |
| Antares Pharma, INC. | $29.47 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $26.71 | 2022-2023 | Nuzyra |
| Aytu Biopharma, INC. | $22.32 | 2021 | |
| Almatica Pharma LLC | $21.38 | 2024 | Loreev Xr |
| Ironwood Pharmaceuticals, INC | $19.98 | 2023 | Linzess |
| Horizon Therapeutics Plc | $19.22 | 2023 | Krystexxa |
| Corium, LLC | $19.10 | 2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $19.01 | 2022 | |
| Seqirus USA INC | $17.62 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Tolmar, INC. | $13.52 | 2023 | |
| Sanofi Pasteur INC. | $13.38 | 2022 | |
| Tris Pharma INC | $12.78 | 2023 | Dyanavel Xr |
| Eyevance Pharmaceuticals LLC | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Midgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.